Iqra Mumal, MSc,  —

Older patients with hereditary angioedema types 1 or 2 can as safely be treated for an acute attack with Firazyr (icatibant) as younger ones, a study found, even though people 65 or older tend to metabolize medicines differently and often are being treated for multiple disorders. The study, “…

Plasma-derived C1-INH concentrate is highly effective in the treatment of patients with acquired angioedema due to C1-inhibitor deficiency — acting fast and significantly shortening attack duration, a study found. The findings were presented at the  2019 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, in a…

There is a significant delay between symptom onset and an accurate diagnosis of hereditary angioedema (HAE) in Brazil, even in patients with a family history of the disease, according to a single-center study. Patients waited an average of 17.7 years from symptom onset to diagnosis, with one experiencing a…

Although the symptoms of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) present in childhood, most patients are diagnosed in adulthood, highlighting a need for increased awareness of C1-INH-HAE among pediatricians, according to a new study. The research, “Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: Icatibant Outcome Survey…

Two signaling pathways — NOTCH2 and NF-kB — are likely involved in both autoimmunity and driving splenic marginal zone lymphoma in patients with acquired angioedema, new research shows. The study, “Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization,” was published in the journal…

Angioedema patients in need to emergency care — being treated at a hospital’s emergency department — most often had an attack linked to bradykinin and medications that target this inflammatory molecule, a study from Croatia reports. Such medications, called RAAS blockers, can be used to treat cardiovascular and kidney…

A study that examined three forms of angioedema suggests there are different processes contributing to the development of each disease. Researchers found that patients with angioedema of unknown cause have significantly different clinical manifestations compared to patients with hereditary angioedema caused by a genetic deficiency in the C1-inhibitor protein. The…

The most common type of angioedema mediated by bradykinin is caused by the use of common blood pressure medications called angiotensin-converting enzyme inhibitors, a review study shows. This is followed by hereditary angioedema and recurrent angioedema, occurring due to an acquired C1-inhibitor deficiency, researchers say. The study, “…

Angioedema can develop, although rarely, in people after they’ve been given angiotensin-converting enzyme (ACE) inhibitors, sometimes years after the therapy is initially administered, according to a new case report. The report, titled “Angioedema Two Weeks After the Initial Administration of an ACE Inhibitor,” was published in…